Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma
Related Experiment Video
Updated: Mar 23, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Christopher M Knapp1, Jia He2, John Lister3
1Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA.
Abstract:
Conventional chemo-immunotherapy fails to cure the majority of mantle cell lymphoma patients and causes substantial toxicity. Resistant mantle cell lymphoma cells commonly overexpress and are dependent on the anti-apoptotic protein, Mcl-1, for survival. In this study, we use potent lipidoid nanoparticles to deliver siRNA to silence Mcl-1 expression. Studies were conducted using two different mantle cell lymphoma cell lines, a normal (JeKo-1) and an aggressive (MAVER-1) line, to assess the ability of lipidoid nanoparticles to be used broadly in the treatment of mantle cell lymphoma. Mcl-1 mRNA silencing and protein knockdown was observed as early as one day after treatment and the lipidoid nanoparticles achieved sustained silencing of Mcl-1 mRNA for at least four days in both JeKo-1 and MAVER-1 cells. Eighty percent silencing was achieved at three days post-transfection in JeKo-1 cells while 50% silencing was achieved in MAVER-1 cells, which are more resistant to transfection. Interestingly, silencing of Mcl-1 induced apoptosis in nearly 30% of both JeKo-1 and MAVER-1 cells three days post-transfection. Additionally, Mcl-1 silencing and the resultant apoptosis in mantle cell lymphoma cells were dose dependent. These data suggest that lipidoid nanoparticles siRNA therapy targeting Mcl-1 has potential as a new treatment modality for mantle cell lymphoma and many other cancers that overexpress Mcl-1. The combination of anti-Mcl-1 lipidoid nanoparticles with other forms of targeted therapy offers hope for reducing or replacing cytotoxic chemotherapy as standard treatment for mantle cell lymphoma.
Insights
Targeting Mcl-1 with lipidoid nanoparticle siRNA therapy effectively silences Mcl-1 expression in mantle cell lymphoma cells, inducing apoptosis. This novel approach shows promise for treating mantle cell lymphoma and other Mcl-1 overexpressing cancers.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Conventional chemo-immunotherapy is often ineffective and toxic for mantle cell lymphoma (MCL) patients.
- MCL cells frequently overexpress the anti-apoptotic protein Mcl-1, which is crucial for their survival.
- Developing targeted therapies that overcome Mcl-1 dependency is critical for improving MCL treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of lipidoid nanoparticles delivering siRNA to silence Mcl-1 expression in MCL cells.
- To assess the broad applicability of this nanoparticle-based siRNA therapy across different MCL cell lines.
- To investigate the potential of Mcl-1 silencing as a therapeutic strategy for MCL.
Main Methods:
- Utilized potent lipidoid nanoparticles to deliver siRNA targeting Mcl-1 mRNA in JeKo-1 (normal) and MAVER-1 (aggressive) MCL cell lines.
- Monitored Mcl-1 mRNA silencing and protein knockdown at various time points post-treatment.
- Quantified the induction of apoptosis in MCL cells following Mcl-1 silencing.
Main Results:
- Achieved significant Mcl-1 mRNA silencing and protein knockdown as early as one day post-treatment, with sustained effects for at least four days.
- Demonstrated dose-dependent Mcl-1 silencing and apoptosis induction in both MCL cell lines.
- Observed approximately 30% apoptosis induction in both cell lines three days post-transfection, with varying silencing efficiencies based on cell line sensitivity.
Conclusions:
- Lipidoid nanoparticle-mediated siRNA delivery effectively targets and silences Mcl-1 in mantle cell lymphoma cells.
- Mcl-1 silencing induces apoptosis in MCL cells, suggesting a potential new therapeutic avenue.
- This Mcl-1 targeting strategy holds promise for treating MCL and other Mcl-1-dependent cancers, potentially reducing reliance on traditional chemotherapy.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:23Abnormal Proliferation